OBJECTIVE: To describe characteristics of Parkinson's disease by sex and determine if differences in disease progression exist. DESIGN: Longitudinal, observational study. SETTING: Twenty-one National Parkinson Foundation Centers of Excellence. PARTICIPANTS: People (N = 4,679; 63% men and 37% women) with idiopathic Parkinson's disease. METHODS: Demographic and clinical data at enrollment and after 1 year were collected. We defined progression as a 1-year change in the following functional health outcome measures: (a) health-related quality of life (Parkinson's Disease Questionnaire-39), (b) Timed Up and Go test, (c) cognitive function, and (d) number of medications. We compared baseline characteristics between men and women. Then, linear regression models were built to assess the independent contribution of sex to progression. RESULTS: At baseline, women were significantly more likely to be older and have greater disease severity and more comorbidities than men despite similar duration of disease. This finding corresponded to worse function as assessed by the Parkinson's Disease Questionnaire-39 and Timed Up and Go test but not to number of medications and cognitive function. After 1 year, declines across all functional measures except delayed recall occurred. No significant changes in Parkinson's Disease Questionnaire-39, Timed Up and Go, number of medications, or verbal fluency between men and women occurred. Women had a more significant improvement in delayed recall than men. CONCLUSION: Numerous small baseline differences occurred between men and women with PD, although differences in markers of progression were few. Findings suggest that clinical manifestations and prognosis appear similar by sex under the same treatment conditions.
OBJECTIVE: To describe characteristics of Parkinson's disease by sex and determine if differences in disease progression exist. DESIGN: Longitudinal, observational study. SETTING: Twenty-one National Parkinson Foundation Centers of Excellence. PARTICIPANTS: People (N = 4,679; 63% men and 37% women) with idiopathic Parkinson's disease. METHODS: Demographic and clinical data at enrollment and after 1 year were collected. We defined progression as a 1-year change in the following functional health outcome measures: (a) health-related quality of life (Parkinson's Disease Questionnaire-39), (b) Timed Up and Go test, (c) cognitive function, and (d) number of medications. We compared baseline characteristics between men and women. Then, linear regression models were built to assess the independent contribution of sex to progression. RESULTS: At baseline, women were significantly more likely to be older and have greater disease severity and more comorbidities than men despite similar duration of disease. This finding corresponded to worse function as assessed by the Parkinson's Disease Questionnaire-39 and Timed Up and Go test but not to number of medications and cognitive function. After 1 year, declines across all functional measures except delayed recall occurred. No significant changes in Parkinson's Disease Questionnaire-39, Timed Up and Go, number of medications, or verbal fluency between men and women occurred. Women had a more significant improvement in delayed recall than men. CONCLUSION: Numerous small baseline differences occurred between men and women with PD, although differences in markers of progression were few. Findings suggest that clinical manifestations and prognosis appear similar by sex under the same treatment conditions.
Authors: Christopher G Goetz; Werner Poewe; Olivier Rascol; Cristina Sampaio; Glenn T Stebbins; Carl Counsell; Nir Giladi; Robert G Holloway; Charity G Moore; Gregor K Wenning; Melvin D Yahr; Lisa Seidl Journal: Mov Disord Date: 2004-09 Impact factor: 10.338
Authors: Kelvin L Chou; Melissa M Amick; Jason Brandt; Richard Camicioli; Karen Frei; Darren Gitelman; Jennifer Goldman; John Growdon; Howard I Hurtig; Bonnie Levin; Irene Litvan; Laura Marsh; Tanya Simuni; Alexander I Tröster; Ergun Y Uc Journal: Mov Disord Date: 2010-11-15 Impact factor: 10.338
Authors: Elizabeth L Stegemöller; Joe Nocera; Irene Malaty; Mack Shelley; Michael S Okun; Chris J Hass Journal: Arch Phys Med Rehabil Date: 2013-11-27 Impact factor: 3.966
Authors: Marina Picillo; Marianna Amboni; Roberto Erro; Katia Longo; Carmine Vitale; Marcello Moccia; Angela Pierro; Gabriella Santangelo; Anna De Rosa; Giuseppe De Michele; Lucio Santoro; Giuseppe Orefice; Paolo Barone; Maria Teresa Pellecchia Journal: J Neurol Date: 2013-08-30 Impact factor: 4.849
Authors: Erika F Augustine; Adriana Pérez; Rohit Dhall; Chizoba C Umeh; Aleksandar Videnovic; Franca Cambi; Anne-Marie A Wills; Jordan J Elm; Richard M Zweig; Lisa M Shulman; Martha A Nance; Jacquelyn Bainbridge; Oksana Suchowersky Journal: PLoS One Date: 2015-07-14 Impact factor: 3.240
Authors: Michelle E Fullard; Dylan P Thibault; Veronica Todaro; Susan Foster; Lori Katz; Robin Morgan; Drew S Kern; Jason M Schwalb; Enrique Urrea Mendoza; Nabila Dahodwala; Lisa Shulman; Allison W Willis Journal: Parkinsonism Relat Disord Date: 2017-12-14 Impact factor: 4.891
Authors: Michael A Schwarzschild; Eric A Macklin; Rachit Bakshi; Shamik Battacharyya; Robert Logan; Alberto J Espay; Albert Y Hung; Grace Bwala; Christopher G Goetz; David S Russell; John L Goudreau; Sotirios A Parashos; Marie H Saint-Hilaire; Alice Rudolph; Joshua M Hare; Gary C Curhan; Alberto Ascherio Journal: Neurology Date: 2019-09-04 Impact factor: 9.910
Authors: Madelyn C Houser; Jianjun Chang; Stewart A Factor; Eric S Molho; Cyrus P Zabetian; Erin M Hill-Burns; Haydeh Payami; Vicki S Hertzberg; Malú G Tansey Journal: Mov Disord Date: 2018-03-23 Impact factor: 10.338
Authors: Laura M Cox; Hadi Abou-El-Hassan; Amir Hadi Maghzi; Julia Vincentini; Howard L Weiner Journal: Brain Res Date: 2019-08-13 Impact factor: 3.252
Authors: Tyler Harrison Reekes; Christopher Ian Higginson; Christina Raye Ledbetter; Niroshan Sathivadivel; Richard Matthew Zweig; Elizabeth Ann Disbrow Journal: NPJ Parkinsons Dis Date: 2020-04-08